Get the Weekly Intelligence Brief — top committee picks every Sunday.
SNY · NASDAQ · STOCK

Sanofi

Healthcare Updated August 11, 2026
$43.56
52W $40.89 – $52.68
62/100
$104.60B
23.1
0.28
AI Committee Verdict
Insufficient Data
62/100
Conviction: Low Data · 67% agreement · 3 analysts
Low Data

Is SNY Bullish or Bearish?

Mixed. Innellis AI committee rates Sanofi (SNY) Insufficient Data with a composite score of 62/100 , based on 3 analysts with 67% agreement. Last updated August 11, 2026.

What Would Change This View

No threshold can be published for SNY. The committee has not produced a scored recommendation, so there is no line for it to cross. Innellis does not infer one.

Executive Summary

Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.

Bull & Bear Case

Bull Case
  • Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Price structure making lower highs and lower lows — Technical
  • MACD histogram negative -- bearish momentum — Technical
  • Trend and market structure agree -- coherent bearish picture — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
62/100
Agreement
67%
Analysts
3
Conviction
Low Data
Sector Rank
Top 32%
of 192 Healthcare peers
Technical Analyst neutral
49 / 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement
− Price structure making lower highs and lower lows
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
60 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
53.1
Neutral
MACD Histogram
-0.037
Bearish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Lh Ll
Support
$43.34
Resistance
$45.24
Bollinger %B
0.47
Inside Bands
Price vs Moving Averages
EMA 9
$43.37 Above
EMA 21
$43.43 Above
EMA 50
$43.63 Below
EMA 200
$45.78 Below

Fundamental Analysis

Valuation
89
Profitability
64
Financial Health
58
Cash Flow
70
Valuation
P/E Ratio 23.1×
P/B Ratio 1.30×
PEG Ratio -0.35
Dividend Yield 5.46%
52W High $52.68
52W Low $40.89
Quality & Growth
ROE 1094.6%
ROA 616.1%
Gross Margin 7276.5%
Operating Margin 2058.1%
Revenue Growth YoY
Debt / Equity 0.34
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 23.1 (inexpensive relative to a 15-40x range); Price-to-book of 1.3x; PEG ratio of -0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 10.9%; Return on assets of 6.2%; Net margin of 8.1%; Gross margin of 72.8%; Current ratio of 0.99 (tight short-term liquidity); Debt-to-equity of 0.34; Free cash flow per share is positive (6.89); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full SNY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore SNY Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime